<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.2 20060430//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title>Breast Cancer Research</journal-title><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">bcr1503</article-id><article-id pub-id-type="pmid">16776850</article-id><article-id pub-id-type="doi">10.1186/bcr1503</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>T&#x000ea;tu</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>bernard.tetu@chuq.qc.ca</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Brisson</surname><given-names>Jacques</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jbrisson@uresp.ulaval.ca</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Wang</surname><given-names>Chang Shu</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>chang.shu.wang@chuq.qc.ca</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Lapointe</surname><given-names>H&#x000e9;l&#x000e8;ne</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A5" contrib-type="author"><name><surname>Beaudry</surname><given-names>Genevi&#x000e8;ve</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>genevievebeaudry@sympatico.ca</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Blanchette</surname><given-names>Caty</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>cblanche@uresp.ulaval.ca</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Trudel</surname><given-names>Dominique</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cardinalt@hotmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Pathology, Laval University, Qu&#x000e9;bec, Canada</aff><aff id="I2"><label>2</label>Centre de Recherche en Canc&#x000e9;rologie, Laval University, Qu&#x000e9;bec, Canada</aff><aff id="I3"><label>3</label>Unit&#x000e9; de Recherche en Sant&#x000e9; des Populations, Laval University, Qu&#x000e9;bec, Canada</aff><pub-date pub-type="ppub"><year>2006</year></pub-date><pub-date pub-type="epub"><day>15</day><month>6</month><year>2006</year></pub-date><volume>8</volume><issue>3</issue><fpage>R28</fpage><lpage>R28</lpage><ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/8/3/R28"/><history><date date-type="received"><day>3</day><month>6</month><year>2005</year></date><date date-type="rev-request"><day>17</day><month>8</month><year>2005</year></date><date date-type="rev-recd"><day>22</day><month>5</month><year>2006</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 T&#x000ea;tu et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>T&#x000ea;tu et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> T&#x000ea;tu Bernard bernard.tetu@chuq.qc.ca </dc:author><dc:title> The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>Breast Cancer Research 8(3): R28-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1465-5411(2006)8:3&#x0003c;R28&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1465-5411</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Introduction</title><p>Matrix metalloproteinase (MMP)-2 is very active at degrading extracellular matrix. It is under the influence of an activator, membrane type 1 MMP (MMP-14), and the tissue inhibitor of metalloproteases (TIMP)-2. We hypothesized that the individual expression of these three markers or their balance may help to predict breast cancer prognosis.</p></sec><sec sec-type="methods"><title>Methods</title><p>MMP-2, MMP-14 and TIMP-2 expression has been evaluated by 35S mRNA <italic>in situ </italic>hybridization on paraffin material of 539 breast cancers without distant metastasis at diagnosis and with a median follow-up of 9.2 years.</p></sec><sec><title>Results</title><p>MMP-2 and MMP-14 mRNA was detected primarily in reactive stromal cells whereas TIMP-2 mRNA was expressed by both stromal and cancer cells. Of the three molecules, an adjusted Cox model revealed that high MMP-14 mRNA (&#x02265; 10% cells) alone predicted a significantly shorter overall survival (<italic>p </italic>= 0.031) when adjusted for clinical factors (tumor size and number of involved lymph nodes). Prognostic significance was lost when further adjusted for Her-2/neu and urokinase-type plasminogen activator (<italic>p </italic>= 0.284). Furthermore, when all three components were analyzed together, the survival was worst for patients with high MMP-2/high MMP-14/low TIMP-2 (5 year survival = 60%) and best with low MMP-2/low MMP-14/high TIMP-2 (5 year survival = 74%), but the difference did not reach statistical significance (<italic>p </italic>= 0.3285).</p></sec><sec><title>Conclusion</title><p>Of the MMP-14/TIMP-2/MMP-2 complex, MMP-14 was the factor most significantly associated with the outcome of breast cancer and was an independent factor of poor overall survival when adjusted for clinical prognostic factors, but not for certain ancillary markers.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>In breast cancer, matrix metalloproteinase (MMP)-2 is a protease produced essentially by stromal cells. <italic>In vitro </italic>studies have clearly demonstrated that it degrades molecules that are abundant in the extracellular matrix (ECM) [<xref ref-type="bibr" rid="B1">1</xref>]. MMP-2 is also one of the major targets of recently developed synthetic MMP inhibitors [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. However, recent literature demonstrates that the mechanism of action of MMP-2 is complex and that other molecules modulate its activity [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>MMP-2 is secreted in an inactive pro-enzymatic form and, unlike other MMPs, its activity is modulated by tissue inhibitor of metalloproteases (TIMP)-2 [<xref ref-type="bibr" rid="B6">6</xref>] and the membrane type 1 MMP (MMP-14) [<xref ref-type="bibr" rid="B7">7</xref>]. Using zymography, breast cancers were found to express higher levels of activated MMP-2 than benign lesions [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>] and <italic>in vitro </italic>studies showed that activated MMP-2 only is associated with an aggressive potential in breast cancer cell lines [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Animal studies showed that carcinoma cell lines transfected with MMP-14 produced higher levels of active MMP-2 and developed more lung metastases compared to parent tumor cells [<xref ref-type="bibr" rid="B11">11</xref>]. TIMP-2 inhibits most if not all activated MMPs and was shown to form a complex specifically with pro-MMP-2 [<xref ref-type="bibr" rid="B12">12</xref>]. However, the role of TIMP-2 is ambiguous since, in addition to its inhibitory effect, it is a main player in the MMP-2 activation cascade [<xref ref-type="bibr" rid="B13">13</xref>]. However, clinical studies on breast cancer are rare, limited in size and do not address the potential interaction of all three factors (MMP-2, MMP-14 and TIMP-2).</p><p>This prompted us to test the hypothesis that the individual expression or the balance between MMP-2, MMP-14 and TIMP-2 expression may help to predict breast cancer prognosis.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Population</title><p>The patients included in this study had node-positive or node-negative disease proven by histological examination of axillary lymph nodes, but with absence of distant metastases at diagnosis. The surgery for breast carcinoma was performed between 1 January 1980 and 31 December 1986. Clinical information was obtained from the patients' charts by experienced research nurses. The tumor size, and number of examined and positive lymph nodes were obtained from the pathology reports. The histological types along with the histological and nuclear grades were reassessed by one of us (BT). The project has been approved by the Laval University Ethical Review board.</p></sec><sec><title><italic>In situ </italic>hybridization</title><p>MMP-2, MMP-14 and TIMP-2 expression was analyzed by <italic>in situ </italic>hybridization. The technique used was a modification of the method of Wolf and colleagues [<xref ref-type="bibr" rid="B14">14</xref>] as described before [<xref ref-type="bibr" rid="B15">15</xref>]. S<sup>35 </sup>labeled antisense RNA probes were used. Plasmids were kindly provided by the late Prof. Paul Basset, IGBMC, Illkirch, France (MMP-2 and MMP-14) and the late Dr Anna Kossakowska, Calgary, Alberta (TIMP-2). cDNA inserts were prepared from breast cancer cDNA libraries, subcloned in pBluescript II (MMP-2 and MMP-14) and pBS KS- (TIMP-2) vectors and were used as templates for <italic>in vitro </italic>transcription to generate sense and anti-sense probes. The 2,124 base-pair (bp) MMP-2 cDNA was subcloned in the <italic>Eco</italic>RI site and extended from nucleotide 26 to 2,150; the 1,159 bp MMP-14 cDNA was subcloned in the <italic>Eco</italic>R1 site and extended from nucleotide 454 to 1,613; and the 210 bp TIMP-2 cDNA was subcloned in the <italic>Hin</italic>dIII/<italic>Bam</italic>H1 site. Reduction of the probe length was achieved by partial alkaline hydrolysis. The quality of RNA preservation has been assessed with the use of antisense RNA probes for &#x003b2;-actin and negative controls were obtained with the use of sense probes. <italic>In situ </italic>hybridization for MMP-11 and urokinase-type plasminogen activator (uPA) were performed on all cases as previously described [<xref ref-type="bibr" rid="B15">15</xref>].</p></sec><sec><title>Immunohistochemistry</title><p>In addition to <italic>in situ </italic>hybridization, an immunohistochemical study was performed using the avidin-biotin complex (ABC) method as described before [<xref ref-type="bibr" rid="B15">15</xref>]. Studies were performed using primary antibodies to cathepsin D (Novocastra, Newcastle, UK; dilution, 1/200), p53 (Signet Labs, Dedham, MA, USA; ID labs, London, Ontario, Canada; dilution, 1/50), the heat-shock protein of 27 kDa (HSP-27, Hu27, Dr Jacques Landry, H&#x000f4;tel-Dieu de Qu&#x000e9;bec, Canada; dilution, 1/200), and HER-2/neu (Triton Biosciences, Alameda, CA, USA; dilution, 1/15). For each antibody, positivity was defined by the presence of at least 10% of cells expressing the marker. P53 expression was nuclear, HER-2/neu was membranous and HSP-27 was cytoplasmic.</p></sec><sec><title>Flow cytometry</title><p>DNA flow cytometric analysis was performed in all cases on formalin fixed-paraffin embedded tissues using the method described by Dressler and colleagues [<xref ref-type="bibr" rid="B16">16</xref>]. Ploidy and S-phase fraction were determined on single parameter histograms with the use of ModFit<sup>&#x000ae; </sup>(Verity Software House Inc., Topsham, ME, USA). Debris were excluded with the use of the 'Single Cut' algorithm. G0, G1 and G2 M were defined from a Gaussian curve while S-phase fraction was evaluated with the trapezoid model. All cases with a coefficient of variation exceeding 8% were excluded; the coefficient of variation averaged 6.1% (range 2.5% to 8.0%).</p></sec><sec><title>Hormone receptors</title><p>Estrogen and progesterone receptor measurement was obtained from the patient charts. In the early 1980s, analyses were performed using the hydroxylapatite method [<xref ref-type="bibr" rid="B17">17</xref>]. Positivity was defined by hormone levels above 10 fmol/mg proteins.</p></sec><sec><title>Interpretation</title><p>The light microscopic interpretation of <italic>in situ </italic>hybridization was done by two of us (BT, DT) without knowledge of the clinical information. The scoring was assessed separately on cancer and stromal cells using a semi-quantitative scale similar to that used for immunohistochemistry. For each cell compartment, the percentage of cancer or stromal cells expressing the marker (0%, &#x0003c;10%, 10% to 50%, &#x0003e;50%) was evaluated on the whole tumor surface of one representative section.</p></sec><sec><title>Statistical analysis</title><p>Distant-metastasis-free and overall survival (OS) curves were obtained for each protease according to Kaplan and Meier [<xref ref-type="bibr" rid="B18">18</xref>]. The difference between the curves was assessed using the log-rank test [<xref ref-type="bibr" rid="B19">19</xref>]. Correlation between protease expression and other recognized prognostic variables in breast cancer was determined by the Chi-square test [<xref ref-type="bibr" rid="B19">19</xref>]. Distant-metastasis-free and OS curves were generated using 10% as the cutoff point between those expressing low (negative) or high (positive) protease levels by stromal cells, as defined before [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. The Cox proportional hazard model was used to evaluate the relationship between the expression of each protease, or a combination of more than one protease, and recurrence or death, adjusting for other known or suspected prognostic factors [<xref ref-type="bibr" rid="B21">21</xref>]. Hazard ratios for the occurrence of distant metastases or death of patients with any of the above combinations were obtained by univariate and multivariate analyses.</p></sec></sec><sec><title>Results</title><p>In our tumor bank, information for MMP-2 was available from 610 breast cancers, from 544 for MMP-14 and from 549 cases for TIMP-2. Results for all three molecules were available from 539 cases and all analyses have been performed on this group of patients. The patients' ages ranged from 29 to 72 years (average, 57.3). Of these patients, 190 (35.3%) were node-negative, 340 (63.1%) had node invasion, and the node status was unknown in 9 (1.6%). At last follow-up, 258 (47.9%) were alive and the follow-up of surviving patients ranged from 5.2 to 14.6 years (average, 9.5 years); 21 (3.9%) were lost to follow-up.</p><p>In this study, stromal cells expressed high MMP-2 (Figure <xref ref-type="fig" rid="F1">1a</xref>) in 263 (48.8%) cases, high MMP-14 (Figure <xref ref-type="fig" rid="F1">1b</xref>) in 164 (30.4%) cases and high TIMP-2 (Figure <xref ref-type="fig" rid="F1">1c</xref>) in 200 (37.1%) cases. Furthermore, high TIMP-2 expression by cancer cells (Figure <xref ref-type="fig" rid="F1">1d</xref>) was present in 225 (41.7%) cases while cancer cells expressed MMP-14 in 4 (0.7%) cases and none expressed MMP-2.</p><p>MMP-14 expression by stromal cells was significantly associated with a younger age, lymph node involvement, a ductal histology, HER-2/neu overexpression, and cathepsin D, MMP-11 (stromelysin-3) and uPA expression by stromal cells (Table <xref ref-type="table" rid="T1">1</xref>). MMP-2 expression by stromal cells was associated with lymph node involvement, ductal histology, HER-2/neu and HSP-27 overexpression as well as cathepsin D, MMP-11 and uPA expression by stromal cells. TIMP-2 expression by stromal cells was associated with a ductal histology, and expression of HSP-27 and uPA. TIMP-2 expression by cancer cells was associated with peritumoral lymphovascular invasion, and expression of HSP-27, cathepsin D and uPA by stromal cells.</p><p>Figure <xref ref-type="fig" rid="F2">2</xref> shows the OS curves for each of the three proteases. MMP-2 and MMP-14 expression by cancer cells was not evaluated because too few cases expressed those markers. No difference in OS was found between high and low MMP-2 and between high and low stromal and cancer TIMP-2 expression. However, high MMP-14 expression by stromal cells predicted a shorter survival (<italic>p</italic> = 0.05). In fact, the 5 year survival reached 72.2% for patients whose tumors had low MMP-14 levels as opposed to 64.6% for those with high MMP-14 levels. By multivariate analysis, using the Cox model adjusting for tumor size and number of involved lymph nodes, high MMP-14 expression was clearly a significant factor of poor survival (Table <xref ref-type="table" rid="T2">2</xref>). The statistical significance was lost when HER-2/neu and uPA were included in the model. A trend was found for the association of MMP-14 expression and metastasis-free survival (<italic>p </italic>= 0.08). Indeed, the 5 year metastasis-free survival was 64.0% for patients with low MMP-14 as opposed to 54.3% for those with high MMP-14.</p><p>Figure <xref ref-type="fig" rid="F3">3</xref> shows the overall survival curve considering the balance between MMP-2, MMP-14 and TIMP-2. Of the different combinations, OS was worst for those patients with high stromal MMP-2/high stromal MMP-14/low stromal TIMP-2 (60.3% survival at 5 years) and best with low stromal MMP-2/low stromal MMP-14/high stromal TIMP-2 (74.4% survival at 5 years). This difference did not, however, reach significance (<italic>p </italic>= 0.25).</p></sec><sec><title>Discussion</title><p>This study confirms the complexity of the role of proteases on breast cancer prognosis. However, the prognostic influence of MMP-2 expression is not clear in the literature. Talvensaari-Mattila and colleagues [<xref ref-type="bibr" rid="B22">22</xref>], Sivula and colleagues [<xref ref-type="bibr" rid="B23">23</xref>] and Pacheco and colleagues [<xref ref-type="bibr" rid="B24">24</xref>] are among the few investigators who demonstrated a significant association between high MMP-2 mRNA or protein expression levels and a poor outcome. In our study of close to 600 cases, MMP-2 overexpression predicted a 15% greater risk of recurrence [<xref ref-type="bibr" rid="B15">15</xref>] but the association of MMP-2 expression with prognosis was not statistically significant. Other studies have failed to relate MMP-2 expression to a poorer prognosis [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. These data are consistent with the complexity of the biology of MMP-2. In our study, they may also be explained in part by the fact that <italic>in situ </italic>hybridization cannot differentiate between the active and inactive forms.</p><p>In our study, when each factor was taken separately, and after adjustment for clinical prognostic factors, only MMP-14 was a significant factor of survival, suggesting that MMP-14 may be one of the key steps in tumor invasion and metastasis. However, the prognostic significance of MMP-14 was not independent of HER-2/neu and uPA. This finding can be explained by the strong regulatory interaction between HER-2/neu, uPA and MMPs [<xref ref-type="bibr" rid="B26">26</xref>]. Indeed, HER-2/neu was found to induce uPA expression and to directly up-regulate MMP expression via transcription factor-binding sites [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>However, the association of MMP-14 but not MMP-2 expression with survival may be explained by the fact that MMP-14 has many substrates other than MMP-2. Indeed, <italic>in vitro </italic>and clinical studies support the major role played by MMP-14 on ECM remodeling. MMP-14 acts either directly by degrading ECM components such as type III collagen or indirectly by activating pro-MMP-2 and also by inducing highly vascularized tumors through vascular endothelial growth factor (VEGF) up-regulation [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. MMP-14 also induces functional activation of the integrin &#x003b1;V&#x003b2;3, which binds to MMP-2 and increases vitronectin-mediated adhesion and migration of MCF7 cells [<xref ref-type="bibr" rid="B31">31</xref>]. Among prior clinical studies, high MMP-14 mRNA expression was an independent factor of both tumor invasion and lymph node metastasis in carcinoma of stomach [<xref ref-type="bibr" rid="B32">32</xref>], lung [<xref ref-type="bibr" rid="B33">33</xref>] and cervix [<xref ref-type="bibr" rid="B34">34</xref>]. In breast cancer, highest expression of MMP-14 by RT-PCR was found in cases with lymph node metastases [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>], poor clinical stage and larger tumor size [<xref ref-type="bibr" rid="B36">36</xref>].</p><p>In our study, MMP-14 mRNA was located in reactive stromal cells close to cancer cells. This is consistent with data from the literature [<xref ref-type="bibr" rid="B37">37</xref>] that identified MMP-14 mRNA within myofibroblasts [<xref ref-type="bibr" rid="B38">38</xref>]. However, the location of MMP-14 in breast tissue is debated and others found MMP-14 mRNA in cancer cells [<xref ref-type="bibr" rid="B39">39</xref>]. Using immunohistochemistry, MMP-14 was located within either stromal and/or cancer cells [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B43">43</xref>].</p><p>In our study, TIMP-2 did not provide independent prognostic information. In the literature on breast cancer, the role of TIMP-2 was controversial. This may explain contradictory results in which patients with higher TIMP-2 expression either experienced low cancer recurrence/progression [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>] or a poor prognosis [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B46">46</xref>-<xref ref-type="bibr" rid="B49">49</xref>], emphasizing the overall activating or inhibitory role of TIMP-2. These contradictory findings may be explained by the versatile role of TIMP-2 [<xref ref-type="bibr" rid="B12">12</xref>]. Indeed, TIMP-2 increases growth rates of murine, bovine and human cells [<xref ref-type="bibr" rid="B50">50</xref>], but also inhibits tumor growth and angiogenesis in melanoma B16F10 cells [<xref ref-type="bibr" rid="B51">51</xref>], attenuates migration of MDA-MB23 breast cancer cells through a bone marrow fibroblast monolayer [<xref ref-type="bibr" rid="B52">52</xref>] and abolishes the tumor-promoting effect of fibroblasts on MCF7 cells injected with matrigel in nude mice [<xref ref-type="bibr" rid="B53">53</xref>].</p><p>The relationship of survival with the combination of MMP-2, MMP-14 and TIMP-2, although not statistically significant, showed that survival was worst for those patients with high MMP-2/high MMP-14/low TIMP-2 and best with low MMP-2/low MMP-14/high TIMP-2. This lack of statistical significance may be explained by the sample size, which may be too small to reach significance, or by the versatile role of TIMP-2, which may be either a favorable or an unfavorable factor. Different combinations of proteases and protease inhibitors or activators have been investigated in the literature but clinical studies are limited and involve few patients. Clinical studies suggest that TIMP-2, or the ratio of MMP-2 and TIMP-2 expression, may play a critical role on cancer progression. For example, higher MMP-2/TIMP-2 ratios were associated with recurrences in patients with bladder [<xref ref-type="bibr" rid="B54">54</xref>] or uterine cervix [<xref ref-type="bibr" rid="B55">55</xref>] cancer. In a study on 14 patients, Onisto and colleagues [<xref ref-type="bibr" rid="B56">56</xref>] report that a high MMP-2/TIMP-2 ratio correlated with lymph node metastases in breast cancer while it predicted a better outcome in another study [<xref ref-type="bibr" rid="B25">25</xref>].</p></sec><sec><title>Conclusion</title><p>Our data show that, of the three proteases studied, MMP-14 was most strongly associated with breast cancer prognosis but was not independent of HER-2/neu or uPA, which may limit its usefulness as a prognostic marker. When all three proteases are studied in combination, a tendency was found for tumors with high MMP-2, high MMP-14 and low TIMP-2 expression to predict a poor prognosis but the results did not reach significance.</p></sec><sec><title>Abbreviations</title><p>bp = base-pair; ECM = extracellular matrix; HSP = heat-shock protein; MMP = matrix metalloproteinase; OS = overall survival; TIMP = tissue inhibitor of metalloproteases; uPA = urokinase-type plasminogen activator.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>BT, JB, CSW, and DT participated in the design of the study. CSW, HL and GB developed and prepared all <italic>in situ </italic>hybridization analyses. BT and DT interpreted all <italic>in situ </italic>hybridization slides. JB supervised the statistical analysis, which was carried out by CB. All authors participated to the discussion on the significance of the results, the drafting of the manuscript and approved the final version.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Sources of support: project supported by the Cancer Research Society Inc. Data base has been raised through a grant from the National Cancer Institute of Canada with funds from the Canadian Cancer Society, the Canadian Breast Cancer Foundation and a joint program from the 'Fonds de la Recherche en Sant&#x000e9; du Qu&#x000e9;bec' and Hydro-Qu&#x000e9;bec. Dr T&#x000ea;tu was recipient of a research clinical scholarship of the 'Fonds de la Recherche en Sant&#x000e9; du Qu&#x000e9;bec' when he completed this project.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Visse</surname><given-names>R</given-names></name><name><surname>Nagase</surname><given-names>H</given-names></name></person-group><article-title>Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry</article-title><source>Circ Res</source><year>2003</year><volume>92</volume><fpage>827</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">12730128</pub-id><pub-id pub-id-type="doi">10.1161/01.RES.0000070112.80711.3D</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>PD</given-names></name><name><surname>Giavazzi</surname><given-names>R</given-names></name></person-group><article-title>Matrix metalloproteinase inhibition: a review of anti-tumour activity</article-title><source>Ann Oncol</source><year>1995</year><volume>6</volume><fpage>967</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">8750146</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vihinen</surname><given-names>P</given-names></name><name><surname>Kahari</surname><given-names>VM</given-names></name></person-group><article-title>Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets</article-title><source>Int J Cancer</source><year>2002</year><volume>99</volume><fpage>157</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">11979428</pub-id><pub-id pub-id-type="doi">10.1002/ijc.10329</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sternlicht</surname><given-names>MD</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>How matrix metalloproteinases regulate cell behavior</article-title><source>Annu Rev Cell Dev Biol</source><year>2001</year><volume>17</volume><fpage>463</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">11687497</pub-id><pub-id pub-id-type="doi">10.1146/annurev.cellbio.17.1.463</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bigg</surname><given-names>HF</given-names></name><name><surname>Morrison</surname><given-names>CJ</given-names></name><name><surname>Butler</surname><given-names>GS</given-names></name><name><surname>Bogoyevitch</surname><given-names>MA</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Soloway</surname><given-names>PD</given-names></name><name><surname>Overall</surname><given-names>CM</given-names></name></person-group><article-title>Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3610</fpage><lpage>3618</lpage><pub-id pub-id-type="pmid">11325829</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name><name><surname>Brown</surname><given-names>PD</given-names></name><name><surname>Onisto</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>AT</given-names></name><name><surname>Liotta</surname><given-names>LA</given-names></name></person-group><article-title>Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues</article-title><source>J Biol Chem</source><year>1990</year><volume>265</volume><fpage>13933</fpage><lpage>13938</lpage><pub-id pub-id-type="pmid">2380196</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deryugina</surname><given-names>EI</given-names></name><name><surname>Ratnikov</surname><given-names>B</given-names></name><name><surname>Monosov</surname><given-names>E</given-names></name><name><surname>Postnova</surname><given-names>TI</given-names></name><name><surname>DiScipio</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>JW</given-names></name><name><surname>Strongin</surname><given-names>AY</given-names></name></person-group><article-title>MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells</article-title><source>Exp Cell Res</source><year>2001</year><volume>263</volume><fpage>209</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">11161720</pub-id><pub-id pub-id-type="doi">10.1006/excr.2000.5118</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Rha</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Roh</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name></person-group><article-title>Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression</article-title><source>Clin Exp Metast</source><year>1996</year><volume>14</volume><fpage>512</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1007/BF00115111</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Remacle</surname><given-names>AG</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name><name><surname>Duggan</surname><given-names>C</given-names></name><name><surname>McDermott</surname><given-names>E</given-names></name><name><surname>O'Higgins</surname><given-names>N</given-names></name><name><surname>Foidart</surname><given-names>JM</given-names></name><name><surname>Duffy</surname><given-names>MJ</given-names></name></person-group><article-title>Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>926</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">9528836</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Azzam</surname><given-names>HS</given-names></name><name><surname>Arand</surname><given-names>G</given-names></name><name><surname>Lippman</surname><given-names>ME</given-names></name><name><surname>Thompson</surname><given-names>EW</given-names></name></person-group><article-title>Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production</article-title><source>J Natl Cancer Inst</source><year>1993</year><volume>85</volume><fpage>1758</fpage><lpage>1764</lpage><pub-id pub-id-type="pmid">8411260</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsunezuka</surname><given-names>Y</given-names></name><name><surname>Kinoh</surname><given-names>H</given-names></name><name><surname>Takino</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>okada</surname><given-names>Y</given-names></name><name><surname>Shinagawa</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name></person-group><article-title>Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>5678</fpage><lpage>5683</lpage><pub-id pub-id-type="pmid">8971175</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>AH</given-names></name><name><surname>Edwards</surname><given-names>DR</given-names></name><name><surname>Murphy</surname><given-names>G</given-names></name></person-group><article-title>Metalloproteinase inhibitors: biological actions and therapeutic opportunities</article-title><source>J Cell Sci</source><year>2002</year><volume>115</volume><fpage>3719</fpage><lpage>3727</lpage><pub-id pub-id-type="pmid">12235282</pub-id><pub-id pub-id-type="doi">10.1242/jcs.00063</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bachmeier</surname><given-names>BE</given-names></name><name><surname>Iancu</surname><given-names>CM</given-names></name><name><surname>Jochum</surname><given-names>M</given-names></name><name><surname>Nerlich</surname><given-names>AG</given-names></name></person-group><article-title>Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach</article-title><source>Expert Rev Anticancer Ther</source><year>2005</year><volume>5</volume><fpage>149</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">15757447</pub-id><pub-id pub-id-type="doi">10.1586/14737140.5.1.149</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Rouyer</surname><given-names>N</given-names></name><name><surname>Lutz</surname><given-names>Y</given-names></name><name><surname>Adida</surname><given-names>C</given-names></name><name><surname>Loriot</surname><given-names>M</given-names></name><name><surname>Bellocq</surname><given-names>JP</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>Stromelysin-3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>1843</fpage><lpage>1847</lpage><pub-id pub-id-type="pmid">8446598</pub-id><pub-id pub-id-type="doi">10.1073/pnas.90.5.1843</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>T&#x000ea;tu</surname><given-names>B</given-names></name><name><surname>Brisson</surname><given-names>J</given-names></name><name><surname>Lapointe</surname><given-names>H</given-names></name><name><surname>Bernard</surname><given-names>P</given-names></name></person-group><article-title>Prognostic significance of stromelysin 3, gelatinase A and urokinase expression in breast cancer</article-title><source>Hum Pathol</source><year>1998</year><volume>29</volume><fpage>979</fpage><lpage>985</lpage><pub-id pub-id-type="pmid">9744315</pub-id><pub-id pub-id-type="doi">10.1016/S0046-8177(98)90204-0</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dressler</surname><given-names>LG</given-names></name><name><surname>Bartow</surname><given-names>SA</given-names></name></person-group><article-title>DNA flow cytometry in solid tumors: practical aspects and clinical applications</article-title><source>Semin Diagn Pathol</source><year>1989</year><volume>6</volume><fpage>55</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">2645625</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Erdos</surname><given-names>T</given-names></name><name><surname>Best-Belpomme</surname><given-names>M</given-names></name><name><surname>Bessada</surname><given-names>R</given-names></name></person-group><article-title>A rapid assay for binding estradiol to uterine receptor(s)</article-title><source>Anal Biochem</source><year>1970</year><volume>37</volume><fpage>244</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">5476182</pub-id><pub-id pub-id-type="doi">10.1016/0003-2697(70)90044-8</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><article-title>Non-parametric estimation from incomplete observations</article-title><source>J Am Stat Assoc</source><year>1958</year><volume>53</volume><fpage>453</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.2307/2281868</pub-id></citation></ref><ref id="B19"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>P</given-names></name></person-group><source>Statistical Methods in Medical Research</source><year>1991</year><publisher-name>New York: John Wiley &#x00026; Sons</publisher-name></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>T&#x000ea;tu</surname><given-names>B</given-names></name><name><surname>Brisson</surname><given-names>J</given-names></name><name><surname>C&#x000f4;t&#x000e9;</surname><given-names>C</given-names></name><name><surname>Brisson</surname><given-names>S</given-names></name><name><surname>Potvin</surname><given-names>D</given-names></name><name><surname>Roberge</surname><given-names>N</given-names></name></person-group><article-title>Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study</article-title><source>Int J Cancer</source><year>1993</year><volume>55</volume><fpage>429</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">8397164</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>DR</given-names></name></person-group><article-title>Regression models and lifetables (with discussion)</article-title><source>J R Statist Soc</source><year>1972</year><volume>34</volume><fpage>187</fpage><lpage>220</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Talvensaari-Mattila</surname><given-names>A</given-names></name><name><surname>Paakko</surname><given-names>P</given-names></name><name><surname>Blanco-Sequeiros</surname><given-names>G</given-names></name><name><surname>Turpeenniemi-Hujanen</surname><given-names>T</given-names></name></person-group><article-title>Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy</article-title><source>Breast Cancer Res Treat</source><year>2001</year><volume>65</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">11245340</pub-id><pub-id pub-id-type="doi">10.1023/A:1006458601568</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sivula</surname><given-names>A</given-names></name><name><surname>Talvensaari-Mattila</surname><given-names>A</given-names></name><name><surname>Lundin</surname><given-names>J</given-names></name><name><surname>Joensuu</surname><given-names>H</given-names></name><name><surname>Haglund</surname><given-names>C</given-names></name><name><surname>Ristimaki</surname><given-names>A</given-names></name><name><surname>Turpeenniemi-Hujanen</surname><given-names>T</given-names></name></person-group><article-title>Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2005</year><volume>89</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">15754118</pub-id><pub-id pub-id-type="doi">10.1007/s10549-004-0714-4</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pacheco</surname><given-names>MM</given-names></name><name><surname>Mourao</surname><given-names>M</given-names></name><name><surname>Mantovani</surname><given-names>EB</given-names></name><name><surname>Nishimoto</surname><given-names>IN</given-names></name><name><surname>Brentani</surname><given-names>MM</given-names></name></person-group><article-title>Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations</article-title><source>Clin Exp Metastasis</source><year>1998</year><volume>16</volume><fpage>577</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">9932604</pub-id><pub-id pub-id-type="doi">10.1023/A:1006580415796</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakopoulou</surname><given-names>L</given-names></name><name><surname>Tsirmpa</surname><given-names>I</given-names></name><name><surname>Alexandrou</surname><given-names>P</given-names></name><name><surname>Louvrou</surname><given-names>A</given-names></name><name><surname>Ampela</surname><given-names>C</given-names></name><name><surname>Markaki</surname><given-names>S</given-names></name><name><surname>Davaris</surname><given-names>PS</given-names></name></person-group><article-title>MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival</article-title><source>Breast Cancer Res Treat</source><year>2003</year><volume>77</volume><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">12602913</pub-id><pub-id pub-id-type="doi">10.1023/A:1021371028777</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>MC</given-names></name><name><surname>Chang</surname><given-names>HC</given-names></name><name><surname>Hung</surname><given-names>WC</given-names></name></person-group><article-title>HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>4718</fpage><lpage>4725</lpage><pub-id pub-id-type="pmid">16377629</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M510937200</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohuchi</surname><given-names>E</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name></person-group><article-title>Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>2446</fpage><lpage>2451</lpage><pub-id pub-id-type="pmid">8999957</pub-id><pub-id pub-id-type="doi">10.1074/jbc.272.4.2446</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>d'Ortho</surname><given-names>MP</given-names></name><name><surname>Will</surname><given-names>H</given-names></name><name><surname>Atkinson</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>G</given-names></name><name><surname>Messent</surname><given-names>A</given-names></name><name><surname>Gavrilovic</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Timpl</surname><given-names>R</given-names></name><name><surname>Zardi</surname><given-names>L</given-names></name><name><surname>Murphy</surname><given-names>G</given-names></name></person-group><article-title>Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases</article-title><source>Eur J Biochem</source><year>1997</year><volume>250</volume><fpage>751</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">9461298</pub-id><pub-id pub-id-type="doi">10.1111/j.1432-1033.1997.00751.x</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>SJ</given-names></name></person-group><article-title>Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>9135</fpage><lpage>9140</lpage><pub-id pub-id-type="pmid">8621565</pub-id><pub-id pub-id-type="doi">10.1074/jbc.271.21.12639</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sounni</surname><given-names>NE</given-names></name><name><surname>Devy</surname><given-names>L</given-names></name><name><surname>Hajitou</surname><given-names>A</given-names></name><name><surname>Frankenne</surname><given-names>F</given-names></name><name><surname>Munaut</surname><given-names>C</given-names></name><name><surname>Gilles</surname><given-names>C</given-names></name><name><surname>Deroanne</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>EW</given-names></name><name><surname>Foidart</surname><given-names>JM</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name></person-group><article-title>MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression</article-title><source>FASEB J</source><year>2002</year><volume>16</volume><fpage>555</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">11919158</pub-id><pub-id pub-id-type="doi">10.1096/fj.01-0790com</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deryugina</surname><given-names>EI</given-names></name><name><surname>Bourdon</surname><given-names>MA</given-names></name><name><surname>Jungwirth</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>JW</given-names></name><name><surname>Strongin</surname><given-names>AY</given-names></name></person-group><article-title>Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase</article-title><source>Int J Cancer</source><year>2000</year><volume>86</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10728589</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(20000401)86:1&#x0003c;15::AID-IJC3&#x0003e;3.0.CO;2-B</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Mimori</surname><given-names>K</given-names></name><name><surname>Shiraishi</surname><given-names>T</given-names></name><name><surname>Fujie</surname><given-names>T</given-names></name><name><surname>Baba</surname><given-names>K</given-names></name><name><surname>Kusumoto</surname><given-names>H</given-names></name><name><surname>Haraguchi</surname><given-names>M</given-names></name><name><surname>Ueo</surname><given-names>H</given-names></name><name><surname>Akiyoshi</surname><given-names>T</given-names></name></person-group><article-title>Analysis of MT1-MMP and MMP2 expression in human gastric cancers</article-title><source>Int J Cancer</source><year>1997</year><volume>74</volume><fpage>316</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">9221811</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19970620)74:3&#x0003c;316::AID-IJC14&#x0003e;3.0.CO;2-9</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsunezuka</surname><given-names>Y</given-names></name><name><surname>Kinoh</surname><given-names>H</given-names></name><name><surname>Takino</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Shinagawa</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name></person-group><article-title>Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>5678</fpage><lpage>5683</lpage><pub-id pub-id-type="pmid">8971175</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilles</surname><given-names>C</given-names></name><name><surname>Polette</surname><given-names>M</given-names></name><name><surname>Piette</surname><given-names>J</given-names></name><name><surname>Munaut</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>EW</given-names></name><name><surname>Birembaut</surname><given-names>P</given-names></name><name><surname>Foidart</surname><given-names>JM</given-names></name></person-group><article-title>High level of MT-MMP expression is associated with invasiveness of cervical cancer cells</article-title><source>Int J Cancer</source><year>1996</year><volume>65</volume><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">8567119</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19960117)65:2&#x0003c;209::AID-IJC14&#x0003e;3.0.CO;2-8</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mimori</surname><given-names>K</given-names></name><name><surname>Ueo</surname><given-names>H</given-names></name><name><surname>Shirasaka</surname><given-names>C</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name></person-group><article-title>Clinical significance of MT1-MMP mRNA expression in breast cancer</article-title><source>Oncol Rep</source><year>2001</year><volume>8</volume><fpage>401</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">11182063</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name></person-group><article-title>Expression and tissue localization of membrane-types 1,2, and 3 matrix metalloproteinases in human invasive breast carcinomas</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>2055</fpage><lpage>2060</lpage><pub-id pub-id-type="pmid">9158005</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polette</surname><given-names>M</given-names></name><name><surname>Gilles</surname><given-names>C</given-names></name><name><surname>Marchand</surname><given-names>V</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name><name><surname>Tournier</surname><given-names>JM</given-names></name><name><surname>Birembaut</surname><given-names>P</given-names></name></person-group><article-title>Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells</article-title><source>Clin Exp Metastasis</source><year>1997</year><volume>15</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">9062392</pub-id><pub-id pub-id-type="doi">10.1023/A:1018404927753</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bisson</surname><given-names>C</given-names></name><name><surname>Blacher</surname><given-names>S</given-names></name><name><surname>Polette</surname><given-names>M</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>Kebers</surname><given-names>F</given-names></name><name><surname>Desreux</surname><given-names>J</given-names></name><name><surname>Tetu</surname><given-names>B</given-names></name><name><surname>Rosenbaum</surname><given-names>J</given-names></name><name><surname>Foidart</surname><given-names>JM</given-names></name><name><surname>Birembaut</surname><given-names>P</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name></person-group><article-title>Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells</article-title><source>Int J Cancer</source><year>2003</year><volume>105</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12672023</pub-id><pub-id pub-id-type="doi">10.1002/ijc.11012</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalberg</surname><given-names>K</given-names></name><name><surname>Eriksson</surname><given-names>E</given-names></name><name><surname>Enberg</surname><given-names>U</given-names></name><name><surname>Kjellman</surname><given-names>M</given-names></name><name><surname>Backdahl</surname><given-names>M</given-names></name></person-group><article-title>Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer</article-title><source>World J Surg</source><year>2000</year><volume>24</volume><fpage>334</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">10658069</pub-id><pub-id pub-id-type="doi">10.1007/s002689910053</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>JL</given-names></name><name><surname>Glynn</surname><given-names>P</given-names></name><name><surname>Walker</surname><given-names>RA</given-names></name></person-group><article-title>Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas</article-title><source>J Pathol</source><year>1999</year><volume>189</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">10547569</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(199910)189:2&#x0003c;161::AID-PATH406&#x0003e;3.0.CO;2-2</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishigaki</surname><given-names>S</given-names></name><name><surname>Toi</surname><given-names>M</given-names></name><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>H</given-names></name><name><surname>Muta</surname><given-names>M</given-names></name><name><surname>Koike</surname><given-names>M</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name></person-group><article-title>Significance of membrane type 1 matrix metalloproteinase expression in breast cancer</article-title><source>Jpn J Cancer Res</source><year>1999</year><volume>90</volume><fpage>516</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">10391091</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strongin</surname><given-names>AY</given-names></name><name><surname>Collier</surname><given-names>I</given-names></name><name><surname>Bannikiv</surname><given-names>G</given-names></name><name><surname>Marmer</surname><given-names>BL</given-names></name><name><surname>Grants</surname><given-names>GA</given-names></name><name><surname>Goldberg</surname><given-names>GI</given-names></name></person-group><article-title>Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>5331</fpage><lpage>5338</lpage><pub-id pub-id-type="pmid">7890645</pub-id><pub-id pub-id-type="doi">10.1074/jbc.270.10.5331</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>A</given-names></name><name><surname>Bellocq</surname><given-names>JP</given-names></name><name><surname>Rouyer</surname><given-names>N</given-names></name><name><surname>Chenard</surname><given-names>MP</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast and head and neck carcinomas</article-title><source>Proc Natl Acad Sci USA</source><year>1995</year><volume>92</volume><fpage>2730</fpage><lpage>2734</lpage><pub-id pub-id-type="pmid">7708715</pub-id><pub-id pub-id-type="doi">10.1073/pnas.92.7.2730</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorogh</surname><given-names>T</given-names></name><name><surname>Beier</surname><given-names>UH</given-names></name><name><surname>Baumken</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>JE</given-names></name><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Gottschlich</surname><given-names>S</given-names></name><name><surname>Maune</surname><given-names>S</given-names></name></person-group><article-title>Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas</article-title><source>Head Neck</source><year>2006</year><volume>28</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">16265652</pub-id><pub-id pub-id-type="doi">10.1002/hed.20298</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giannelli</surname><given-names>G</given-names></name><name><surname>Bergamini</surname><given-names>C</given-names></name><name><surname>Marinosci</surname><given-names>F</given-names></name><name><surname>Fransvea</surname><given-names>E</given-names></name><name><surname>Quaranta</surname><given-names>M</given-names></name><name><surname>Lupo</surname><given-names>L</given-names></name><name><surname>Schiraldi</surname><given-names>O</given-names></name><name><surname>Antonaci</surname><given-names>S</given-names></name></person-group><article-title>Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma</article-title><source>Int J Cancer</source><year>2002</year><volume>97</volume><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">11802202</pub-id><pub-id pub-id-type="doi">10.1002/ijc.1635</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Visscher</surname><given-names>DW</given-names></name><name><surname>Hoyhtya</surname><given-names>H</given-names></name><name><surname>Ottosen</surname><given-names>SK</given-names></name><name><surname>Liang</surname><given-names>CM</given-names></name><name><surname>Sarkar</surname><given-names>FH</given-names></name><name><surname>Crissman</surname><given-names>JD</given-names></name><name><surname>Friedman</surname><given-names>R</given-names></name></person-group><article-title>Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence</article-title><source>Int J Cancer</source><year>1994</year><volume>59</volume><fpage>339</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">7927938</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruokolainen</surname><given-names>H</given-names></name><name><surname>Paakko</surname><given-names>P</given-names></name><name><surname>Turpeenniemi-Hujanen</surname><given-names>T</given-names></name></person-group><article-title>Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma &#x02013; tissue immunoreactivity predicts aggressive clinical course</article-title><source>Mod Pathol</source><year>2006</year><volume>19</volume><fpage>208</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">16424893</pub-id><pub-id pub-id-type="doi">10.1038/modpathol.3800506</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katayama</surname><given-names>A</given-names></name><name><surname>Bandoh</surname><given-names>N</given-names></name><name><surname>Kishibe</surname><given-names>K</given-names></name><name><surname>Takahara</surname><given-names>M</given-names></name><name><surname>Ogino</surname><given-names>T</given-names></name><name><surname>Nonaka</surname><given-names>S</given-names></name><name><surname>Harabuchi</surname><given-names>Y</given-names></name></person-group><article-title>Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>634</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">14760086</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-0864-02</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Kaur</surname><given-names>P</given-names></name><name><surname>Sheehan</surname><given-names>CE</given-names></name><name><surname>Fisher</surname><given-names>HA</given-names></name><name><surname>Kaufman</surname><given-names>RA</given-names><suffix>Jr</suffix></name><name><surname>Kallakury</surname><given-names>BV</given-names></name></person-group><article-title>Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer</article-title><source>Mod Pathol</source><year>2003</year><volume>16</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">12640098</pub-id><pub-id pub-id-type="doi">10.1097/01.MP.0000056984.62360.6C</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Ohuchi</surname><given-names>E</given-names></name><name><surname>Shinagawa</surname><given-names>A</given-names></name></person-group><article-title>Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2)</article-title><source>J Cell Sci</source><year>1994</year><volume>107</volume><fpage>2373</fpage><lpage>2379</lpage><pub-id pub-id-type="pmid">7844157</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valente</surname><given-names>P</given-names></name><name><surname>Fassina</surname><given-names>G</given-names></name><name><surname>Melchiori</surname><given-names>A</given-names></name><name><surname>Masiello</surname><given-names>L</given-names></name><name><surname>Cilli</surname><given-names>M</given-names></name><name><surname>Vacca</surname><given-names>A</given-names></name><name><surname>Onisto</surname><given-names>M</given-names></name><name><surname>Santi</surname><given-names>L</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name><name><surname>Albini</surname><given-names>A</given-names></name></person-group><article-title>TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis</article-title><source>Int J Cancer</source><year>1998</year><volume>75</volume><fpage>246</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">9462715</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19980119)75:2&#x0003c;246::AID-IJC13&#x0003e;3.0.CO;2-B</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saad</surname><given-names>S</given-names></name><name><surname>Bendall</surname><given-names>LJ</given-names></name><name><surname>James</surname><given-names>A</given-names></name><name><surname>Gottlieb</surname><given-names>DJ</given-names></name><name><surname>Bradstock</surname><given-names>KF</given-names></name></person-group><article-title>Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts</article-title><source>Breast Cancer Res Treat</source><year>2000</year><volume>63</volume><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">11097087</pub-id><pub-id pub-id-type="doi">10.1023/A:1006437530169</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noel</surname><given-names>AC</given-names></name><name><surname>Hajitou</surname><given-names>A</given-names></name><name><surname>L'Hoir</surname><given-names>C</given-names></name><name><surname>Maquoi</surname><given-names>E</given-names></name><name><surname>Baramova</surname><given-names>E</given-names></name><name><surname>Lewalle</surname><given-names>JM</given-names></name><name><surname>Remacle</surname><given-names>AG</given-names></name><name><surname>Kevers</surname><given-names>F</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Calberg-Bacq</surname><given-names>CM</given-names></name><name><surname>Foidart</surname><given-names>JM</given-names></name></person-group><article-title>Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts</article-title><source>Int J Cancer</source><year>1998</year><volume>76</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">9537590</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19980413)76:2&#x0003c;267::AID-IJC15&#x0003e;3.0.CO;2-9</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gohji</surname><given-names>K</given-names></name><name><surname>Fujimoto</surname><given-names>N</given-names></name><name><surname>Fujii</surname><given-names>A</given-names></name><name><surname>Komiyama</surname><given-names>T</given-names></name><name><surname>Okawa</surname><given-names>J</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name></person-group><article-title>Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>3196</fpage><lpage>3198</lpage><pub-id pub-id-type="pmid">8764105</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nuovo</surname><given-names>GL</given-names></name><name><surname>MacConnell</surname><given-names>PB</given-names></name><name><surname>Simsir</surname><given-names>A</given-names></name><name><surname>Valea</surname><given-names>F</given-names></name><name><surname>French</surname><given-names>DL</given-names></name></person-group><article-title>Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>267</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">7812956</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onisto</surname><given-names>M</given-names></name><name><surname>Riccio</surname><given-names>MP</given-names></name><name><surname>Scannapieco</surname><given-names>P</given-names></name><name><surname>Caenazzo</surname><given-names>C</given-names></name><name><surname>Griggio</surname><given-names>L</given-names></name><name><surname>Spina</surname><given-names>M</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name><name><surname>Garbisa</surname><given-names>S</given-names></name></person-group><article-title>Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR</article-title><source>Int J Cancer</source><year>1995</year><volume>63</volume><fpage>621</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">7591276</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Expression of matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of metalloproteases (TIMP)-2 in stromal and cancer cells. <bold>(a) </bold>MMP-2 expression by stromal cells (<italic>in situ </italic>hybridization, &#x000d7; 200); <bold>(b) </bold>MMP-14 expression by stromal cells (<italic>in situ </italic>hybridization, &#x000d7; 200); <bold>(c) </bold>TIMP-2 expression by stromal cells (<italic>in situ </italic>hybridization, &#x000d7; 200); <bold>(d) </bold>TIMP-2 expression by cancer cells (<italic>in situ </italic>hybridization, &#x000d7; 200). Scale bar = 200 microns. C, cancer cells; S, stromal cells.</p></caption><graphic xlink:href="bcr1503-1"></graphic></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Overall survival for matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of metalloproteases (TIMP)-2 expression by stromal and cancer cells. Overall survival curves for: <bold>(a) </bold>matrix metalloproteinase (MMP)-2 expressed by stromal cells; <bold>(b) </bold>MMP-14 expressed by stromal cells; <bold>(c) </bold>tissue inhibitor of metalloproteases (TIMP)-2 expressed by stromal cells; and <bold>(d) </bold>TIMP-2 expressed by cancer cells (<italic>p </italic>values obtained by the log-rank test).</p></caption><graphic xlink:href="bcr1503-2"></graphic></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Overall survival curves for: matrix metalloproteinase (MMP)-2, MMP-14 and stromal tissue inhibitor of metalloproteases (TIMP)-2 (<italic>p </italic>values obtained by the log-rank test).</p></caption><graphic xlink:href="bcr1503-3"></graphic></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Association of high protease expression by stromal cells with other prognostic factors</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Parameter</td><td align="center">Cases</td><td align="center" colspan="3">MMP-14</td><td align="center" colspan="3">MMP-2</td><td align="center" colspan="3">TIMP-2: stromal cells</td><td align="center" colspan="3">TIMP-2: cancer cells</td></tr></thead><tbody><tr><td></td><td></td><td align="center">Number</td><td align="center">Percentage Pos</td><td align="center"><italic>p </italic>value</td><td align="center">Number</td><td align="center">Pecentage Pos</td><td align="center"><italic>p </italic>value</td><td align="center">Number</td><td align="center">Percentage Pos</td><td align="center"><italic>p </italic>value</td><td align="center">Number</td><td align="center">Percentage Pos</td><td align="center"><italic>p </italic>value</td></tr><tr><td colspan="14"><hr></hr></td></tr><tr><td align="left">Age years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x0003c;50</td><td align="center">160</td><td align="center">59</td><td align="center">36.9</td><td align="center">0.034</td><td align="center">85</td><td align="center">53.1</td><td align="center">0.19</td><td align="center">58</td><td align="center">36.3</td><td align="center">0.79</td><td align="center">59</td><td align="center">36.9</td><td align="center">0.14</td></tr><tr><td align="left">&#x02003;&#x02265;50</td><td align="center">379</td><td align="center">105</td><td align="center">27.7</td><td></td><td align="center">178</td><td align="center">47.0</td><td></td><td align="center">142</td><td align="center">37.5</td><td></td><td align="center">166</td><td align="center">43.8</td><td></td></tr><tr><td align="left">Tumor size cm</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x0003c;3</td><td align="center">297</td><td align="center">93</td><td align="center">31.3</td><td align="center">0.98</td><td align="center">146</td><td align="center">49.2</td><td align="center">0.65</td><td align="center">118</td><td align="center">39.7</td><td align="center">0.14</td><td align="center">122</td><td align="center">41.1</td><td align="center">0.83</td></tr><tr><td align="left">&#x02003;&#x02265;3</td><td align="center">207</td><td align="center">65</td><td align="center">31.4</td><td></td><td align="center">106</td><td align="center">51.2</td><td></td><td align="center">69</td><td align="center">33.3</td><td></td><td align="center">87</td><td align="center">42.0</td><td></td></tr><tr><td align="left">Involved lymph nodes</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;0</td><td align="center">190</td><td align="center">46</td><td align="center">24.2</td><td></td><td align="center">81</td><td align="center">42.6</td><td></td><td align="center">71</td><td align="center">37.4</td><td></td><td align="center">80</td><td align="center">42.1</td><td></td></tr><tr><td align="left">&#x02003;1 to 3</td><td align="center">166</td><td align="center">61</td><td align="center">36.7</td><td align="center">0.036</td><td align="center">93</td><td align="center">56.0</td><td align="center">0.041</td><td align="center">69</td><td align="center">41.6</td><td align="center">0.29</td><td align="center">75</td><td align="center">45.2</td><td align="center">0.52</td></tr><tr><td align="left">&#x02003;&#x0003e;3</td><td align="center">174</td><td align="center">54</td><td align="center">31.0</td><td></td><td align="center">84</td><td align="center">48.3</td><td></td><td align="center">58</td><td align="center">33.3</td><td></td><td align="center">68</td><td align="center">39.1</td><td></td></tr><tr><td align="left">Peritumoral lymphovascular invasion</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Yes</td><td align="center">143</td><td align="center">50</td><td align="center">35.0</td><td align="center">0.15</td><td align="center">76</td><td align="center">53.1</td><td align="center">0.097</td><td align="center">50</td><td align="center">35.0</td><td align="center">0.15</td><td align="center">64</td><td align="center">44.8</td><td align="center">0.027</td></tr><tr><td align="left">&#x02003;No</td><td align="center">75</td><td align="center">19</td><td align="center">25.3</td><td></td><td align="center">31</td><td align="center">41.3</td><td></td><td align="center">19</td><td align="center">25.3</td><td></td><td align="center">22</td><td align="center">29.3</td><td></td></tr><tr><td align="left">Histological grade</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;I</td><td align="center">54</td><td align="center">18</td><td align="center">33.3</td><td></td><td align="center">25</td><td align="center">46.3</td><td></td><td align="center">19</td><td align="center">35.2</td><td></td><td align="center">23</td><td align="center">42.6</td><td></td></tr><tr><td align="left">&#x02003;II</td><td align="center">277</td><td align="center">81</td><td align="center">29.2</td><td align="center">0.69</td><td align="center">133</td><td align="center">48.0</td><td align="center">0.83</td><td align="center">109</td><td align="center">39.4</td><td align="center">0.59</td><td align="center">119</td><td align="center">42.9</td><td align="center">0.82</td></tr><tr><td align="left">&#x02003;III</td><td align="center">197</td><td align="center">64</td><td align="center">32.5</td><td></td><td align="center">99</td><td align="center">50.3</td><td></td><td align="center">69</td><td align="center">35.0</td><td></td><td align="center">79</td><td align="center">40.1</td><td></td></tr><tr><td align="left">Nuclear grade</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;I</td><td align="center">94</td><td align="center">20</td><td align="center">21.3</td><td></td><td align="center">40</td><td align="center">42.6</td><td></td><td align="center">39</td><td align="center">41.5</td><td></td><td align="center">42</td><td align="center">44.7</td><td></td></tr><tr><td align="left">&#x02003;II</td><td align="center">307</td><td align="center">98</td><td align="center">31.9</td><td align="center">0.066</td><td align="center">158</td><td align="center">51.5</td><td align="center">0.27</td><td align="center">105</td><td align="center">34.2</td><td align="center">0.22</td><td align="center">128</td><td align="center">41.7</td><td align="center">0.79</td></tr><tr><td align="left">&#x02003;III</td><td align="center">127</td><td align="center">45</td><td align="center">35.4</td><td></td><td align="center">59</td><td align="center">46.5</td><td></td><td align="center">53</td><td align="center">41.7</td><td></td><td align="center">51</td><td align="center">40.2</td><td></td></tr><tr><td align="left">Histological type</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Invasive ductal carcinoma</td><td align="center">470</td><td align="center">156</td><td align="center">33.2</td><td align="center">0.0006</td><td align="center">238</td><td align="center">50.6</td><td align="center">0.021</td><td align="center">164</td><td align="center">34.9</td><td align="center">0.003</td><td align="center">28</td><td align="center">43.1</td><td align="center">0.83</td></tr><tr><td align="left">&#x02003;Others</td><td align="center">65</td><td align="center">8</td><td align="center">12.3</td><td></td><td align="center">23</td><td align="center">35.4</td><td></td><td align="center">35</td><td align="center">53.8</td><td></td><td align="center">196</td><td align="center">41.7</td><td></td></tr><tr><td align="left">DNA ploidy</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Diploid</td><td align="center">143</td><td align="center">37</td><td align="center">25.9</td><td align="center">0.09</td><td align="center">64</td><td align="center">44.8</td><td align="center">0.18</td><td align="center">58</td><td align="center">40.6</td><td align="center">0.59</td><td align="center">60</td><td align="center">42.0</td><td align="center">0.99</td></tr><tr><td align="left">&#x02003;Non-diploid</td><td align="center">332</td><td align="center">112</td><td align="center">33.7</td><td></td><td align="center">171</td><td align="center">51.5</td><td></td><td align="center">126</td><td align="center">38.0</td><td></td><td align="center">139</td><td align="center">41.9</td><td></td></tr><tr><td align="left">Estrogen receptors</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">143</td><td align="center">53</td><td align="center">37.1</td><td align="center">0.055</td><td align="center">76</td><td align="center">53.1</td><td align="center">0.22</td><td align="center">59</td><td align="center">41.3</td><td align="center">0.25</td><td align="center">61</td><td align="center">42.7</td><td align="center">0.89</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">374</td><td align="center">106</td><td align="center">28.3</td><td></td><td align="center">176</td><td align="center">47.1</td><td></td><td align="center">134</td><td align="center">35.8</td><td></td><td align="center">157</td><td align="center">42.0</td><td></td></tr><tr><td align="left">Progesterone receptors</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">219</td><td align="center">74</td><td align="center">33.8</td><td align="center">0.21</td><td align="center">109</td><td align="center">49.8</td><td align="center">0.72</td><td align="center">88</td><td align="center">40.2</td><td align="center">0.26</td><td align="center">95</td><td align="center">43.4</td><td align="center">0.60</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">297</td><td align="center">85</td><td align="center">28.6</td><td></td><td align="center">143</td><td align="center">48.1</td><td></td><td align="center">105</td><td align="center">35.4</td><td></td><td align="center">122</td><td align="center">41.1</td><td></td></tr><tr><td align="left">HER-2/neu expression</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">437</td><td align="center">121</td><td align="center">27.7</td><td align="center">0.0042</td><td align="center">204</td><td align="center">46.7</td><td align="center">0.042</td><td align="center">158</td><td align="center">36.2</td><td align="center">0.34</td><td align="center">179</td><td align="center">41.0</td><td align="center">0.45</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">102</td><td align="center">43</td><td align="center">42.2</td><td></td><td align="center">59</td><td align="center">57.8</td><td></td><td align="center">42</td><td align="center">41.2</td><td></td><td align="center">46</td><td align="center">45.1</td><td></td></tr><tr><td align="left">p53</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">374</td><td align="center">107</td><td align="center">28.6</td><td align="center">0.12</td><td align="center">186</td><td align="center">49.7</td><td align="center">0.53</td><td align="center">132</td><td align="center">35.3</td><td align="center">0.24</td><td align="center">149</td><td align="center">39.8</td><td align="center">0.30</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">152</td><td align="center">54</td><td align="center">35.5</td><td></td><td align="center">71</td><td align="center">46.7</td><td></td><td align="center">62</td><td align="center">40.8</td><td></td><td align="center">68</td><td align="center">44.7</td><td></td></tr><tr><td align="left">HSP-27</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">204</td><td align="center">61</td><td align="center">29.9</td><td align="center">0.097</td><td align="center">97</td><td align="center">47.5</td><td align="center">0.02</td><td align="center">63</td><td align="center">30.9</td><td align="center">0.0024</td><td align="center">70</td><td align="center">34.3</td><td align="center">0.0003</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">157</td><td align="center">60</td><td align="center">38.2</td><td></td><td align="center">94</td><td align="center">59.9</td><td></td><td align="center">73</td><td align="center">46.5</td><td></td><td align="center">84</td><td align="center">53.5</td><td></td></tr><tr><td align="left">Cathepsin D cancer cells</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">324</td><td align="center">94</td><td align="center">29.0</td><td align="center">0.29</td><td align="center">151</td><td align="center">46.6</td><td align="center">0.21</td><td align="center">111</td><td align="center">34.3</td><td align="center">0.071</td><td align="center">127</td><td align="center">39.2</td><td align="center">0.102</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">207</td><td align="center">69</td><td align="center">33.3</td><td></td><td align="center">87</td><td align="center">52.2</td><td></td><td align="center">87</td><td align="center">42.0</td><td></td><td align="center">96</td><td align="center">46.4</td><td></td></tr><tr><td align="left">Cathepsin D stromal cells</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">303</td><td align="center">78</td><td align="center">25.7</td><td align="center">0.0035</td><td align="center">130</td><td align="center">42.9</td><td align="center">0.0013</td><td align="center">106</td><td align="center">35.0</td><td align="center">0.21</td><td align="center">116</td><td align="center">38.3</td><td align="center">0.047</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">226</td><td align="center">85</td><td align="center">37.6</td><td></td><td align="center">129</td><td align="center">57.1</td><td></td><td align="center">91</td><td align="center">40.3</td><td></td><td align="center">106</td><td align="center">46.9</td><td></td></tr><tr><td align="left">MMP-11</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">215</td><td align="center">32</td><td align="center">14.9</td><td align="center">&#x0003c;0.0001</td><td align="center">65</td><td align="center">30.2</td><td align="center">&#x0003c;0.0001</td><td align="center">76</td><td align="center">35.3</td><td align="center">0.46</td><td align="center">93</td><td align="center">43.3</td><td align="center">0.60</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">322</td><td align="center">132</td><td align="center">41.0</td><td></td><td align="center">198</td><td align="center">61.5</td><td></td><td align="center">124</td><td align="center">38.5</td><td></td><td align="center">132</td><td align="center">41.0</td><td></td></tr><tr><td align="left">MMP-2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">276</td><td align="center">41</td><td align="center">14.9</td><td align="center">&#x0003c;0.0001</td><td align="center">-</td><td align="center">-</td><td></td><td align="center">89</td><td align="center">32.2</td><td align="center">0.017</td><td align="center">110</td><td align="center">39.9</td><td align="center">0.36</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">263</td><td align="center">123</td><td align="center">46.8</td><td></td><td align="center">-</td><td align="center">-</td><td></td><td align="center">111</td><td align="center">42.2</td><td></td><td align="center">115</td><td align="center">43.7</td><td></td></tr><tr><td align="left">uPA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">374</td><td align="center">81</td><td align="center">21.7</td><td align="center">&#x0003c;0.0001</td><td align="center">147</td><td align="center">39.3</td><td align="center">&#x0003c;0.0001</td><td align="center">127</td><td align="center">34.0</td><td align="center">0.016</td><td align="center">143</td><td align="center">38.2</td><td align="center">0.017</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">160</td><td align="center">81</td><td align="center">50.6</td><td></td><td align="center">115</td><td align="center">71.9</td><td></td><td align="center">72</td><td align="center">45.4</td><td></td><td align="center">79</td><td align="center">49.4</td><td></td></tr></tbody></table><table-wrap-foot><p>HSP, heat-shock protein; MMP, matrix metalloproteinase; Pos, positive; TIMP, tissue inhibitor of metalloproteases; uPA, urokinase-type plasminogen activator.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Hazard ratios for MMP-14, MMP-2, TIMP-2 and combination of MMP-14 MMP-2 TIMP-2 on breast cancer overall survival</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="3">Univariate</td><td align="center" colspan="3">Multivariate<sup>a</sup></td><td align="center" colspan="3">Multivariate<sup>b</sup></td></tr></thead><tbody><tr><td></td><td align="center">HR</td><td align="center">95% CI</td><td align="center"><italic>p </italic>value</td><td align="center">HR</td><td align="center">95% CI</td><td align="center"><italic>p </italic>value</td><td align="center">HR</td><td align="center">95% CI</td><td align="center"><italic>p </italic>value</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left">MMP-14</td><td align="center">1.31</td><td align="center">0.99&#x02013;1.72</td><td align="center">0.05</td><td align="center">1.36</td><td align="center">1.03&#x02013;1.81</td><td align="center">0.031</td><td align="center">1.18</td><td align="center">0.87&#x02013;1.59</td><td align="center">0.28</td></tr><tr><td align="left">MMP-2</td><td align="center">1.14</td><td align="center">0.88&#x02013;1.47</td><td align="center">0.33</td><td align="center">1.14</td><td align="center">0.87&#x02013;1.49</td><td align="center">0.34</td><td align="center">0.98</td><td align="center">0.73&#x02013;1.31</td><td align="center">0.87</td></tr><tr><td align="left">TIMP-2: stromal cells</td><td align="center">0.91</td><td align="center">0.69&#x02013;1.19</td><td align="center">0.51</td><td align="center">1.04</td><td align="center">0.78&#x02013;1.38</td><td align="center">0.79</td><td align="center">0.89</td><td align="center">0.66&#x02013;1.19</td><td align="center">0.43</td></tr><tr><td align="left">TIMP-2: cancer cells</td><td align="center">1.07</td><td align="center">0.83&#x02013;1.39</td><td align="center">0.61</td><td align="center">1.09</td><td align="center">0.83&#x02013;1.43</td><td align="center">0.53</td><td align="center">1.02</td><td align="center">0.77&#x02013;1.34</td><td align="center">0.91</td></tr><tr><td align="left">MMP-14-/MMP-2-/TIMP-2+<sup>c</sup></td><td align="center">1.0</td><td></td><td></td><td align="center">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">MMP-14+/MMP-2+/TIMP-2-</td><td align="center">1.46</td><td align="center">0.89&#x02013;2.38</td><td align="center">0.13</td><td align="center">1.29</td><td align="center">0.77&#x02013;2.16</td><td align="center">0.33</td><td></td><td></td><td></td></tr><tr><td align="left">Other categories</td><td align="center">1.11</td><td align="center">0.76&#x02013;1.63</td><td align="center">0.59</td><td align="center">1.03</td><td align="center">0.68&#x02013;1.55</td><td align="center">0.90</td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Cox model adjusting for tumor size and number of involved lymph nodes. <sup>b</sup>Cox model adjusting for tumor size, number of involved lymph nodes, HER-2/neu and urokinase plasminogen activator. <sup>c</sup>TIMP-2 by stromal cells. CI, confidence interval; HR, hazard ratio; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteases.</p></table-wrap-foot></table-wrap></sec></back></article> 